Sleep Disorders and Cancer: Difference between revisions

m (Grammar, spelling, punctuation edit.)
(Added "treatment options" information.)
Line 15: Line 15:
Sleep disorders in people with cancer are associated with the following: <ref>Walker WH, Borniger JC. [https://www.mdpi.com/1422-0067/20/11/2780 Molecular mechanisms of cancer-induced sleep disruption]. International journal of molecular sciences. 2019 Jun 6;20(11):2780.</ref>
Sleep disorders in people with cancer are associated with the following: <ref>Walker WH, Borniger JC. [https://www.mdpi.com/1422-0067/20/11/2780 Molecular mechanisms of cancer-induced sleep disruption]. International journal of molecular sciences. 2019 Jun 6;20(11):2780.</ref>


* '''Activation of the inflammatory response (even during chemotherapy''': Cytokines activate microglia, thus astrocyte neurotoxic reaction.
* '''Activation of the inflammatory response (even during chemotherapy)''': Cytokines activate microglia, thus astrocyte neurotoxic reaction.
* '''Production of interleukins by tumours''': Interleukin-1 beta (IL-1 β) inhibits REM (rapid eye movement) sleep and affects the neurotransmitters involved in sleep (adenosine, prostaglandins, nitric oxide, GABA). Interleukin-6 (IL-6) produced in high quantities in [[Breast Cancer|breast]], [[Lung Cancer|lung]], liver and [[Prostate Cancer|prostate]] cancer also seems to reduce REM sleep and increase slow-wave sleep.
* '''Production of interleukins by tumours''': Interleukin-1 beta (IL-1 β) inhibits REM (rapid eye movement) sleep and affects the neurotransmitters involved in sleep (adenosine, prostaglandins, nitric oxide, GABA). Interleukin-6 (IL-6) produced in high quantities in [[Breast Cancer|breast]], [[Lung Cancer|lung]], liver and [[Prostate Cancer|prostate]] cancer also seems to reduce REM sleep and increase slow-wave sleep.
* '''The factors activating the hypothalamic orexin (also called hypocretin) neurons''': Ghrelin (correlated with an increase in tumour), leptin (produced in [[Breast Cancer|breast]], [[Prostate Cancer|prostate]], pancreas, ovary, [[Lung Cancer|lung]] and [[Colorectal Cancer|colorectal]] cancer and involved in the proliferation of cancer cells), a reduction in pH, [[hypoglycemia]] and some amino acids.
* '''The factors activating the hypothalamic orexin (also called hypocretin) neurons''': Ghrelin (correlated with an increase in tumour), leptin (produced in [[Breast Cancer|breast]], [[Prostate Cancer|prostate]], pancreas, ovary, [[Lung Cancer|lung]] and [[Colorectal Cancer|colorectal]] cancer and involved in the proliferation of cancer cells), a reduction in pH, [[hypoglycemia]] and some amino acids.
Line 25: Line 25:


== Treatment Options ==
== Treatment Options ==
A review study <ref name=":0" /> summarised the treatment options for sleep disorders in oncology rehabilitation as follows:
* Melatonin <ref>Talib WH. [https://www.mdpi.com/1420-3049/23/3/518 Melatonin and cancer hallmarks]. Molecules. 2018 Feb 26;23(3):518.</ref><ref>Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Najafi M, Sahebkar A. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. Journal of cellular physiology. 2019 May;234(5):5613-27.</ref><ref>Mortezaee K, Najafi M, Farhood B, Ahmadi A, Potes Y, Shabeeb D, Musa AE. [https://www.sciencedirect.com/science/article/abs/pii/S0024320519303479 Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review]. Life sciences. 2019 Jul 1;228:228-41.</ref><ref>Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. Oncotarget 8 (24): 39896–39921.</ref>
* [[Cognitive Behavioural Therapy]] <ref>Aricò D, Raggi A, Ferri R. [https://www.frontiersin.org/articles/10.3389/fpsyg.2016.01162/full Cognitive behavioral therapy for insomnia in breast cancer survivors: a review of the literature]. Frontiers in psychology. 2016 Aug 3;7:1162.</ref><ref>Irwin MR. [https://academic.oup.com/jnci/article/110/8/799/4881761 Innovation in the treatment of insomnia in breast cancer survivors]. JNCI: Journal of the National Cancer Institute. 2018 Aug 1;110(8):799-800.</ref>
* Antidepressants/ GABAergic drugs <ref>Tanimukai H, Murai T, Okazaki N, Matsuda Y, Okamoto Y, Kabeshita Y, Ohno Y, Tsuneto S. An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. American Journal of Hospice and Palliative Medicine®. 2013 Jun;30(4):359-62.</ref><ref>Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S, Tabrizi N, Salehifar E. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040148/ The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial]. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2018;23.</ref>
* Continuous positive air pressure ventilation <ref>Gharib SA, Seiger AN, Hayes AL, Mehra R, Patel SR. [https://academic.oup.com/sleep/article/37/4/709/2416878 Treatment of obstructive sleep apnea alters cancer-associated transcriptional signatures in circulating leukocytes]. Sleep. 2014 Apr 1;37(4):709-14.</ref><ref>Xie X, Pan L, Ren D, Du C, Guo Y. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis. Sleep medicine. 2013 Nov 1;14(11):1139-50.</ref><ref>Baessler A, Nadeem R, Harvey M, Madbouly E, Younus A, Sajid H, Naseem J, Asif A, Bawaadam H. [https://journal-inflammation.biomedcentral.com/articles/10.1186/1476-9255-10-13 Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers-a meta-analysis]. Journal of inflammation. 2013 Dec;10(1):1-0.</ref><ref>Lin CC, Liaw SF, Chiu CH, Chen WJ, Lin MW, Chang FT. Effects of nasal CPAP on exhaled SIRT1 and tumor necrosis factor-α in patients with obstructive sleep apnea. Respiratory physiology & neurobiology. 2016 Jul 1;228:39-46.</ref>
* Orexin and orexin receptor antagonists <ref>Graybill NL, Weissig V. [https://journals.sagepub.com/doi/full/10.1177/2050312117735774 A review of orexin’s unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers]. SAGE open medicine. 2017 Nov 1;5:2050312117735774.</ref><ref>Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. [https://www.frontiersin.org/articles/10.3389/fendo.2018.00573/full The anti-tumoral properties of orexin/hypocretin hypothalamic neuropeptides: an unexpected therapeutic role]. Frontiers in endocrinology. 2018 Sep 27;9:573.</ref><ref>Xu TR, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular signalling. 2013 Dec 1;25(12):2413-23.</ref>
* Chronotherapy <ref>Ozturk N, Ozturk D, Halil Kavakli I, Okyar A. [https://www.mdpi.com/1422-0067/18/10/2168 Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy]. International journal of molecular sciences. 2017 Oct 17;18(10):2168.</ref>


== Resources  ==
== Resources  ==

Revision as of 00:02, 7 November 2023

Original Editor - Sehriban Ozmen

Top Contributors - Sehriban Ozmen, Kapil Narale, Rujuta Naik and Lucinda hampton  

This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (06/11/2023)

Introduction[edit | edit source]

There is a bidirectional correlation between cancer and sleep disorders. This means that having a sleep disorder may increase the risk of developing cancer in the future, and those with cancer are likely to experience sleep disorders during diagnosis, treatment and even ten years of survivorship. [1] [2] On this page, this correlation will be detailed for various sleep and cancer diseases. Underlying causes as well as preventive and curative treatment methods will also be included since sleep disorders decrease the quality of life by affecting the physical and mental health of people with cancer/tumors [1] [2].

Underlying Mechanism[edit | edit source]

Sleep disorders in people with cancer are associated with the following: [3]

  • Activation of the inflammatory response (even during chemotherapy): Cytokines activate microglia, thus astrocyte neurotoxic reaction.
  • Production of interleukins by tumours: Interleukin-1 beta (IL-1 β) inhibits REM (rapid eye movement) sleep and affects the neurotransmitters involved in sleep (adenosine, prostaglandins, nitric oxide, GABA). Interleukin-6 (IL-6) produced in high quantities in breast, lung, liver and prostate cancer also seems to reduce REM sleep and increase slow-wave sleep.
  • The factors activating the hypothalamic orexin (also called hypocretin) neurons: Ghrelin (correlated with an increase in tumour), leptin (produced in breast, prostate, pancreas, ovary, lung and colorectal cancer and involved in the proliferation of cancer cells), a reduction in pH, hypoglycemia and some amino acids.
  • Changes in the serotonergic, dopaminergic, GABAergic and noradrenergic circuits induced by tumours

Sleep Disorders As a Risk Factor in Cancer[edit | edit source]

Cancer Induced Sleep Disorders[edit | edit source]

Treatment Options[edit | edit source]

A review study [1] summarised the treatment options for sleep disorders in oncology rehabilitation as follows:

Resources[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 1.2 Mogavero MP, DelRosso LM, Fanfulla F, Bruni O, Ferri R. Sleep disorders and cancer: State of the art and future perspectives. Sleep Medicine Reviews. 2021 Apr 1;56:101409.
  2. ↑ 2.0 2.1 Büttner-Teleagă A, Kim YT, Osel T, Richter K. Sleep disorders in cancer—a systematic review. International journal of environmental research and public health. 2021 Nov 7;18(21):11696.
  3. ↑ Walker WH, Borniger JC. Molecular mechanisms of cancer-induced sleep disruption. International journal of molecular sciences. 2019 Jun 6;20(11):2780.
  4. ↑ Talib WH. Melatonin and cancer hallmarks. Molecules. 2018 Feb 26;23(3):518.
  5. ↑ Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Najafi M, Sahebkar A. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. Journal of cellular physiology. 2019 May;234(5):5613-27.
  6. ↑ Mortezaee K, Najafi M, Farhood B, Ahmadi A, Potes Y, Shabeeb D, Musa AE. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. Life sciences. 2019 Jul 1;228:228-41.
  7. ↑ Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. Oncotarget 8 (24): 39896–39921.
  8. ↑ Aricò D, Raggi A, Ferri R. Cognitive behavioral therapy for insomnia in breast cancer survivors: a review of the literature. Frontiers in psychology. 2016 Aug 3;7:1162.
  9. ↑ Irwin MR. Innovation in the treatment of insomnia in breast cancer survivors. JNCI: Journal of the National Cancer Institute. 2018 Aug 1;110(8):799-800.
  10. ↑ Tanimukai H, Murai T, Okazaki N, Matsuda Y, Okamoto Y, Kabeshita Y, Ohno Y, Tsuneto S. An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. American Journal of Hospice and Palliative Medicine®. 2013 Jun;30(4):359-62.
  11. ↑ Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S, Tabrizi N, Salehifar E. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2018;23.
  12. ↑ Gharib SA, Seiger AN, Hayes AL, Mehra R, Patel SR. Treatment of obstructive sleep apnea alters cancer-associated transcriptional signatures in circulating leukocytes. Sleep. 2014 Apr 1;37(4):709-14.
  13. ↑ Xie X, Pan L, Ren D, Du C, Guo Y. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis. Sleep medicine. 2013 Nov 1;14(11):1139-50.
  14. ↑ Baessler A, Nadeem R, Harvey M, Madbouly E, Younus A, Sajid H, Naseem J, Asif A, Bawaadam H. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers-a meta-analysis. Journal of inflammation. 2013 Dec;10(1):1-0.
  15. ↑ Lin CC, Liaw SF, Chiu CH, Chen WJ, Lin MW, Chang FT. Effects of nasal CPAP on exhaled SIRT1 and tumor necrosis factor-α in patients with obstructive sleep apnea. Respiratory physiology & neurobiology. 2016 Jul 1;228:39-46.
  16. ↑ Graybill NL, Weissig V. A review of orexin’s unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers. SAGE open medicine. 2017 Nov 1;5:2050312117735774.
  17. ↑ Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The anti-tumoral properties of orexin/hypocretin hypothalamic neuropeptides: an unexpected therapeutic role. Frontiers in endocrinology. 2018 Sep 27;9:573.
  18. ↑ Xu TR, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular signalling. 2013 Dec 1;25(12):2413-23.
  19. ↑ Ozturk N, Ozturk D, Halil Kavakli I, Okyar A. Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy. International journal of molecular sciences. 2017 Oct 17;18(10):2168.
Retrieved from "https://www.physio-pedia.com/index.php?title=Sleep_Disorders_and_Cancer&oldid=343630"